Skip to main content
. 2017 Nov 16;52(2):389–401. doi: 10.3892/ijo.2017.4205

Figure 4.

Figure 4

Conjugation of targeting peptide SP94 to liposomal doxorubicin selectively enhances drug delivery to tumor cells in vivo. NOD.CB17-Prkdcscid/J mice bearing SK-HEP-1 tumors (four mice per time-point) received tail vein injections of either LD or SP94-LD at 1 mg/kg. At selected time-points post-injection, mice were euthanized. Various organs were excised after perfusion with PBS, and analyzed for auto-fluorescent doxorubicin signals. The levels of doxorubicin were quantified with a standard curve generated from the fluorescence emission of known amounts of doxorubicin (N=4). Doxorubicin concentrations in (A) plasma and (B) tumors are shown. (C) Tissue concentrations of doxorubicin in mice administered with either LD or SP94-LD at selected time-points after injection.